Cartesian Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Cartesian Therapeutics
RNAC Stock   6.50  0.01  0.15%   
Cartesian Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Cartesian Therapeutics' valuation are provided below:
Gross Profit
-51.8 M
Market Capitalization
168.8 M
Enterprise Value Revenue
34.576
Revenue
1.1 M
Earnings Share
(1.33)
We have found one hundred twenty available fundamental signals for Cartesian Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Investors should ensure to validate all of Cartesian Therapeutics' prevailing performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 133.5 M, whereas Enterprise Value is forecasted to decline to about 39 M.

Cartesian Therapeutics Total Revenue

30.23 Million

Check Cartesian Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cartesian Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 0.0 or Selling General Administrative of 21.7 M, as well as many indicators such as Price To Sales Ratio of 13.03, Dividend Yield of 0.0 or Days Sales Outstanding of 8.94. Cartesian financial statements analysis is a perfect complement when working with Cartesian Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Cartesian Stock
Check out the analysis of Cartesian Therapeutics Correlation against competitors.
For information on how to trade Cartesian Stock refer to our How to Trade Cartesian Stock guide.

Cartesian Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets525.3 M500.3 M161.5 M
Slightly volatile
Short and Long Term Debt Total23 M16.1 M17.6 M
Slightly volatile
Other Current Liabilities15.5 M22.8 M12.1 M
Slightly volatile
Total Current Liabilities38.1 M26.4 M28.4 M
Slightly volatile
Other Liabilities28.8 M42.4 M23.5 M
Slightly volatile
Property Plant And Equipment Net18.7 M17.8 M7.2 M
Slightly volatile
Current Deferred Revenue2.5 M2.7 M9.3 M
Pretty Stable
Accounts Payable246.2 K259.2 K938.1 K
Very volatile
Cash256.7 M244.5 M89.5 M
Slightly volatile
Non Current Assets Total263.7 M251.2 M60.3 M
Slightly volatile
Other Assets2.3 M1.5 M1.7 M
Pretty Stable
Cash And Short Term Investments256.7 M244.5 M95.3 M
Slightly volatile
Net Receivables952.7 K1 M3.1 M
Slightly volatile
Common Stock Shares Outstanding28.6 M27.2 M6.6 M
Slightly volatile
Liabilities And Stockholders Equity525.3 M500.3 M161.5 M
Slightly volatile
Non Current Liabilities Total505.8 M481.7 M181.4 M
Slightly volatile
Other Current Assets4 M3.6 M3.2 M
Slightly volatile
Other Stockholder Equity833 M793.4 M291.2 M
Slightly volatile
Total Liabilities533.5 M508.1 M209.1 M
Slightly volatile
Deferred Long Term Liabilities404.2 K425.5 K2.5 M
Pretty Stable
Property Plant And Equipment Gross21.5 M20.5 M8.3 M
Slightly volatile
Total Current Assets261.6 M249.1 M101.2 M
Slightly volatile
Common Stock3.3 K3.5 K5 K
Slightly volatile
Property Plant Equipment2.2 M3.2 M2.2 M
Slightly volatile
Common Stock Total Equity18.1 K17.2 K7.4 K
Slightly volatile
Capital Surpluse385.7 M567.3 M333 M
Slightly volatile
Cash And Equivalents96.8 M122.4 M82.3 M
Slightly volatile
Net Working Capital233.8 M222.7 M100.5 M
Slightly volatile
Capital Stock3.3 K3.5 K5.9 K
Slightly volatile
Capital Lease Obligations10.5 M16.1 M5.1 M
Slightly volatile

Cartesian Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.4 M1.3 M1.2 M
Slightly volatile
Selling General Administrative21.7 M34.6 M18 M
Slightly volatile
Total Revenue30.2 M44.7 M22.9 M
Slightly volatile
Gross Profit30 M44.7 M22.8 M
Slightly volatile
Other Operating Expenses73.6 M95.2 M57.6 M
Slightly volatile
Research Development51.1 M51.9 M38.6 M
Slightly volatile
Cost Of Revenue1.3 M1.4 M15.6 M
Slightly volatile
Total Operating Expenses73.1 M95.2 M57.2 M
Slightly volatile
Interest Income8.9 M8.5 M2.3 M
Slightly volatile
Reconciled Depreciation1.2 M1.3 M990.2 K
Slightly volatile

Cartesian Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation7.3 M7.6 M5.4 M
Slightly volatile
Begin Period Cash Flow75.7 M90 M56.2 M
Slightly volatile
Depreciation1.2 M1.3 M1 M
Slightly volatile
Other Non Cash Items62.2 M59.2 M22.2 M
Slightly volatile
Capital Expenditures11 M10.5 M2.3 M
Slightly volatile
End Period Cash Flow258.7 M246.4 M90.2 M
Slightly volatile
Dividends Paid157.3 K165.6 K3.5 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio13.0313.7172.2611
Pretty Stable
Days Sales Outstanding8.949.4188.6326
Pretty Stable
Stock Based Compensation To Revenue0.260.150.33
Slightly volatile
Capex To Depreciation7.477.111.8059
Slightly volatile
EV To Sales7.457.8453.4734
Pretty Stable
Payables Turnover5.165.86.3325
Slightly volatile
Sales General And Administrative To Revenue1.420.891.8585
Slightly volatile
Research And Ddevelopement To Revenue1.271.3318.4346
Very volatile
Capex To Revenue0.520.270.3689
Very volatile
Cash Per Share8.979.4464.0647
Slightly volatile
Days Payables Outstanding45.350.9655.6234
Slightly volatile
Intangibles To Total Assets0.610.530.6305
Slightly volatile
Current Ratio8.918.494.2883
Slightly volatile
Receivables Turnover42.1740.1613.2593
Slightly volatile
Capex Per Share0.380.40.7818
Slightly volatile
Revenue Per Share1.641.739.665
Pretty Stable
Interest Debt Per Share0.590.6219.1096
Slightly volatile
Debt To Assets0.03510.0370.2213
Slightly volatile
Graham Number54.3861.1766.7666
Slightly volatile
Operating Cycle8.949.4188.6326
Pretty Stable
Days Of Payables Outstanding45.350.9655.6234
Slightly volatile
Ebt Per Ebit1.181.581.312
Slightly volatile
Quick Ratio8.918.494.2993
Slightly volatile
Net Income Per E B T1.541.152.1965
Slightly volatile
Cash Ratio8.748.333.6921
Slightly volatile
Days Of Sales Outstanding8.949.4188.6326
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.841.251.0419
Pretty Stable
Fixed Asset Turnover2.482.272.6486
Slightly volatile
Debt Ratio0.03510.0370.2213
Slightly volatile
Price Sales Ratio13.0313.7172.2611
Pretty Stable
Asset Turnover0.140.08050.1588
Pretty Stable
Gross Profit Margin0.780.880.9638
Slightly volatile

Cartesian Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap133.5 M91.5 M154.1 M
Very volatile
Enterprise Value39 M41 M106.6 M
Slightly volatile

Cartesian Fundamental Market Drivers

Forward Price Earnings25.4453
Cash And Short Term Investments212.6 M

Cartesian Upcoming Events

7th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
7th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Cartesian Therapeutics Financial Statements

Cartesian Therapeutics stakeholders use historical fundamental indicators, such as Cartesian Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Cartesian Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cartesian Therapeutics' assets and liabilities are reflected in the revenues and expenses on Cartesian Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cartesian Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue2.7 M2.5 M
Total Revenue44.7 M30.2 M
Cost Of Revenue1.4 M1.3 M
Stock Based Compensation To Revenue 0.15  0.26 
Sales General And Administrative To Revenue 0.89  1.42 
Research And Ddevelopement To Revenue 1.33  1.27 
Capex To Revenue 0.27  0.52 
Revenue Per Share 1.73  1.64 
Ebit Per Revenue(1.02)(1.07)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
When determining whether Cartesian Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cartesian Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cartesian Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cartesian Therapeutics Stock:
How To Invest In Cartesian
Details
Is Cartesian Stock a good investment?
Details
What is Cartesian Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Cartesian Therapeutics Correlation against competitors.
For information on how to trade Cartesian Stock refer to our How to Trade Cartesian Stock guide.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Will Biotechnology sector continue expanding? Could Cartesian diversify its offerings? Factors like these will boost the valuation of Cartesian Therapeutics. Anticipated expansion of Cartesian directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cartesian Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth
(0.07)
Earnings Share
(1.33)
Revenue Per Share
0.042
Quarterly Revenue Growth
0.168
Return On Assets
(0.13)
The market value of Cartesian Therapeutics is measured differently than its book value, which is the value of Cartesian that is recorded on the company's balance sheet. Investors also form their own opinion of Cartesian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cartesian Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Cartesian Therapeutics' market value can be influenced by many factors that don't directly affect Cartesian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Cartesian Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cartesian Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Cartesian Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY